Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 5/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | MPO | P05164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4965121 | 0.83 | CYP1A2 (0.47) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4969106 | 0.82 | NPC1 (0.37) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5146450 | 0.81 | MEN1 (0.35) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2809369 | 0.80 | TLR8 (0.44) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2808428 | 0.79 | TRPV1 (0.38) | NPC1RAB9AMEN1KMT2ALMNA | |
| SCHEMBL5144794 | 0.77 | TLR8 (0.41) | LMNAL3MBTL1PTGESHTT | |
| SCHEMBL5146679 | 0.76 | PTGES (0.33) | NPC1RAB9AMEN1KMT2APTGES | |
| SCHEMBL26968810 | 0.75 | TLR8 (0.43) | NPC1RAB9ASMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL29877302 | 0.75 | TLR8 (0.43) | NPC1RAB9ASMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL2806238 | 0.72 | PTGES (0.37) | NPC1RAB9AMEN1KMT2APTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378102-B2 | Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-02-19 | — | — | US | disclosed |
| US-20100240693-A1 | Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC (US) | 2010-09-23 | — | — | US | disclosed |
| EP-1877056-A2 | OXIME AND HYDROXYLAMINE SUBSTITUTED THIAZOLOÝ4,5-C¨RING COMPOUNDS AND METHODS | Coley Pharmaceutical Group, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007120121-A2 | OXIME AND HYDROXYLAMINE SUBSTITUTED THIAZOLO[4,5-C] RING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240693-A1 | Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods | IL4, IL2, TH | NPC1 4507/4885RAB9A 4402/4885MEN1 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.